A regulatory perspective of clinical trial applications for biological products with particular emphasis on Advanced Therapy Medicinal Products (ATMPs)

Authors


  • Any opinions expressed in this paper are our own, are not necessarily shared by other assessors at the MHRA and cannot be considered to be MHRA or EU policy.
  • This article is published with the permission of the Controller of HMSO and the Queen's Printer for Scotland.

Correspondence

Dr David R. Jones, Clinical Trials Unit, Medicines and Healthcare products Regulatory Agency (MHRA), 151 Buckingham Palace Road, London SW1W 9SZ, UK.

Tel.: +44 20 3080 6469

Fax: +44 20 3118 9803

E-mail: david.jones@mhra.gsi.gov.uk

Abstract

The safety of trial subjects is the tenet that guides the regulatory assessment of a Clinical Trial Authorization application and applies equally to trials involving small molecules and those with biological/biotechnological products, including Advanced Therapy Medicinal Products. The objective of a regulator is to ensure that the potential risk faced by a trial subject is outweighed by the potential benefit to them from taking part in the trial. The focus of the application review is to assess whether risks have been identified and appropriate steps taken to alleviate these as much as possible. Other factors are also taken into account during a review, such as regulatory requirements, and emerging non-clinical and clinical data from other trials on the same or similar products. This paper examines the regulatory review process of a Clinical Trial Authorization application from the perspectives of Quality, Non-Clinical and Clinical Regulatory Assessors at the Medicines and Healthcare products Regulatory Agency. It should be noted that each perspective has highlighted specific issues from their individual competence and that these can be different between the disciplines.

Ancillary